Swiss drugmaker Novartis nudged up its full-year earnings forecast on Thursday, citing strong revenue growth from products ...

Swiss drugmaker Novartis nudged up its full-year earnings forecast on Thursday, citing strong second-quarter sales of key ...

The pharmaceutical company raised its full-year profit guidance as ongoing demand for key drugs fueled growth in ...

An important point about the updated guidelines is the emphasis on individualized treatment of complicated UTIs, recognizing ...

Shareholders might have noticed that Novartis AG ( VTX:NOVN ) filed its second-quarter result this time last week.

Novartis AG beats Q2 2025 expectations, but patent expiries and policy risks loom. Click for my updated look at NVS earnings ...

Novartis is stopping the development of ianalumab in hidradenitis suppurativa (HS) after a Phase IIb proof-of-concept trial ...

Swiss pharmaceutical giant Novartis AG (NYSE:NVS) reported second-quarter 2025 earnings on Thursday and raised its full-year ...

Novartis is launching a $10 billion share buyback to be completed by year-end 2027 as new drug launches accelerate. | ...

In its Q2 earnings call Thursday, Novartis said it is moving quickly to reshore its drug manufacturing operations, but CEO ...

Novartis shares climb on strong Cosentyx sales, franchise growth, and a new malaria drug approval despite political risks.